国家科技重大专项-重大新药创-制耐药结核病药物自主创新及评价关键技术研究（2015-2018年）            （主持） 

        子课题“抗耐药结核新药TBI-001的临床前研究”

中国医学科学院医学与健康科技创新工程项目“放射性核素标记药物及临床前药代动力学关键技术研发”    （参加）

国家科技重大专项-重大新药创-“天然产物活性结构域剖析及全新结构药物发现”（2018-2020年）             （参加）

1. Xu Yang, Xiang Zhang*, and DaliYin; An Eco-Friendly Industrial Fischer Indole Cyclization Process; OrganicProcess Research & Development; 2018, 22, 1115-1118.

2. Xu Yang, Xiang Zhang*, Dali Yin; Insitu intramolecular difluorocarbene-triggered synthesis of2-gem-difluoro-2,3-dihydrobenzofuran-3-ols; Tetrahedron Letters; 2018,59: 2941-2944.

 3. X.Zhang, M. C. Wang, L. Li* & D. L. Yin*; A high-performance liquidchromatography-electronic circular dichroism online method for assessing theabsolute enantiomeric excess and conversion ratio of asymmetric reactions; ScientificReports; 2017，| 7:43278 | DOI: 10.1038/srep43278.

4. 杨旭, 张翔*, 尹大力; 改进的Leuckart⁃Wallach反应合成 4,4⁃二甲基环己胺; 化学研究; 2017,28 (1): 39-43.

5. 赵静, 李莉, 张翔*, 尹大力; 依折麦布关键中间体手性苄位羟基侧链的不对称合成研究；中国药物化学杂志; 2016,26 (4): 313-317.

6. P. Li, X. W. Zhang, Y. Q. Wu, M. S.Cheng, D. F. Zhang, G. Li, Z. Y. Lin, X. Zhang* & H. H. Huang*; Afacile and efficient synthesis of 4H-1,3-benzoxazine-4-one withelectron-withdrawing group derivatives; Tetrahedron Letters; 2015,56: 4683-4685.

7. 张翔, 谢平, 汪小涧, 尹大力*; Synthesis ofroflumilast via regioseletive benzylation strategy;中国药物化学杂志; 2014, 24 (6):450-454.

8. X.Zhang, L. Li*, Y. K. Si & D. L. Yin; ECD spectrometric methods fordetecting the enantioselective enzymatic hydrolysis of racemic3-acetoxy-4-phenyl-β-lactam; Chinese Chemical Letters, 2012,23: 1197-1200.

9. F.F. Lai, Z. W. Shen, H. Wen, J. L. Chen, X. Zhang, P. Lin, D. L. Yin, H.Q. Cui, X. G. Chen; A Morphological identification cell cytotoxicity assay usingcytoplasmlocalized fluorescent probe (CLFP) to distinguish living and deadcells; Biochemical and Biophysical Research Communications; 2017,482 (2): 257-263.

10. C.X. He, L. Preiss, B. Wang, L. Fu, H. Wen, X. Zhang, H. Q. Cui, T. Meier,and D. L. Yin; Structural Simplification of Bedaquiline: the Discovery of 3-(4-(N,N-Dimethylaminomethyl)phenyl)quinoline-DerivedAntitubercular Lead Compounds; ChemMedChem; 2017, 12 (2):106-119.

11. H.Wen，Q. H. Cui, H. Meng，F. F. Lai, S. F. Wang, X. Zhang,X. G. Chen, H. Q. Cui and D. L. Yin; A high-resolution method to assess cellmultinucleation with cytoplasm-localized fluorescent probes; Analyst;2016, 141: 4010-4013.

12. X.J. Xia, X. W. Song, J. M. Xu, J. M. He, J. Peng, X. Zhang, D. J. Jin, Z.Abliz, Y. L. Liu;  Development of avalidated LC–APCI-MS/MS method to study the plasma and tumor distribution ofCHO-PTX intravenous lipid emulsion; Journal of Pharmaceutical and BiomedicalAnalysis; 2016, 117: 532-543.

13. C.X.He, H. Meng, X. Zhang, H. Q. Cui, D. L. Yin; Synthesis andbio-evaluation of phenothiazine derivatives as new antituberculosis agents; ChineseChemical Letters; 2015, 26 (2015): 951-954.

14. J.Z. Miao, H. Q. Cui*, J. Jin, F. F. Lai, H. Wen, X. Zhang, G. F. Ruda, X.G. Chen and D. L. Yin*; Development of 3-alkyl-6-methoxy-7-hydroxychromones(AMHCs) from natural isoflavones, a new class of fluorescent scaffolds forbiological imaging; Chemical communications; 2015, 51:881-884.